Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals (ETON)
:ETON
ETON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.47 - $21.48
Previous CloseN/A
Volume127.06K
Average Volume (3M)364.61K
Market Cap
$468.23M
Enterprise Value$388.54M
Total Cash (Recent Filing)$25.38M
Total Debt (Recent Filing)$3.26M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 12, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding26,817,535
10 Day Avg. Volume297,217
30 Day Avg. Volume364,611
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue6.68
Enterprise Value/Gross Profit11.24
Enterprise Value/Ebitda20.45K
Forecast
1Y Price Target
$27.13Price Target Upside57.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Product DevelopmentET-600, if approved, will be the only FDA-approved oral liquid formulation of desmopressin, positioning the company for a unique market advantage.
Product ExpansionIncrelex has seen a significant increase in patient adoption since its relaunch, with potential for substantial market growth through label expansion.
Revenue GrowthThe company continues to maintain its quarterly revenue growth trajectory with $18.9M, driven by strong performance from Alinkdi Sprinkle and the relaunches of Increlex and Galzin.
Bears Say
Market CompetitionET-600 faces potential competition risks which could impact its market entry and success despite being a unique formulation.
Risks And ChallengesRisks to the Buy rating include clinical, commercial, collaboration, dilution, legal and intellectual property, and competition.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $4.47 and its highest was $21.48 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $468.23M.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.063.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.09.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went up 12.32%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.13 (57.00% Upside)
$27.13 (57.00% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
282.30%
12-Months-Change
Fundamentals
Return on Equity
-22.06%
Trailing 12-Months
Asset Growth
219.50%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with several major achievements in product sales, FDA approvals, and financial performance, despite some challenges related to product labeling and regulatory hurdles.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$27.13
▲(57.00% Upside)
Technical Analysis
Ownership Overview
24.52% Insiders
5.70% Mutual Funds
33.39% Other Institutional Investors
28.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---